Fox Business - The Power to Prosper
Search Site

Mylan

Related Topics

  1. Watson Pharmaceuticals
  2. IMS Health
  3. Corning Inc.
  4. Pfizer
  5. King Pharmaceuticals
  6. Novartis
Get updates on Mylan
Actavis to Buy Warner Chilcott for $5 Billion in Stock

Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands--and shrinking its tax burden.The deal follows reports that Actavis itself was targeted for a takeover by potential bidders including Valeant Pharmaceuticals Inc. (VRX) and Mylan Inc. (MYL). If the Actavis-Warner Chilcott deal is completed, Actavis's lower tax rate could help it better compete with Valeant and others in search of further deals as the generic-drug and specialty-pharmaceutical sectors undergo consolidation.Companies selling niche pharmaceutical brands and low-cost generics are seeking to beef up through mergers and acquisitions to grapple with pricing pressure in developed markets including the U.S. and western Europe, and to capitalize on opportunities for stronger sales growth in emerging markets including Russia and China. Also, a wave of patent expirations for big-selling branded...

Read More ›

  1. Ranbaxy Resumes Generic Lipitor Production for U.S.

    Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following...

  2. A Weakening Yen Weighs on U.S. Earnings

    As the Bank of Japan continues to expand quantitative easing, Wolfgang Koester warns that holders of     U.S. equities will soon start feeling the effect of the weak...

  3. Analysis: Alimta patent seen as Lilly's "wild card"

    Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit.Should an obscure patent on Lilly lung cance...

  4. Mylan Settles Patent Dispute over Parkinson's Treatment

    Mylan Inc.(MYL) reached a settlement in a patent dispute with Finnish pharmaceuticals and diagnostics company Orion Corp. that will allow the U.S. drug maker to laun...

  5. U.S. Appeals Court Rejects Challenge to Crestor Patent

    A federal appeals court Friday upheld a key patent on AstraZeneca PLC's (AZN, AZN.LN) blockbuster cholesterol drug Crestor, rejecting an effort by generic drugmakers...

  6. Moody's Upgrades Mylan Two Notches to Investment Grade

    Moody's Investors Service gave Mylan Inc. (MYL) a two-notch upgrade, raising the generic-drug maker's ratings into investment grade, on expectations the company's st...

  7. EARNINGS PREVIEW: U.S. Drug Makers Struggle With Loss of Exclusivity in 3rd Quarter

    TAKING THE PULSE: Most major U.S. drug makers in the third quarter continued with efforts to cope with the recent losses of market exclusivity for former blockbuster...

  8. FDA Withdrawing Approval of 1 Impax/Teva Generic Wellbutrin Product

    One version of generic Wellbutrin comes off U.S. market-FDA tests show generic not as effective as brand name-FDA asking other drug makers to conduct additional test...

  9. Prescriptions for Merck's Singulair Plunge After Loss of U.S. Patent

    Weekly prescriptions for Merck & Co.'s (MRK) asthma and allergy treatment Singulair plunged nearly 90% within four weeks of the August introduction of competing gene...

  10. Shawn Feliciano Hikes for Multiple Sclerosis

    Shawn Feliciano Garber is on a mission to spread awareness of multiple sclerosis, a disease that affects her and 400,000 other Americans.

  11. Mylan 2Q Earnings Pregame Scorecard

    Last quarter Mylan (NASDAQ:MYL) beat estimates by one cent per share and it is up again on Thursday, July 26, 2012.ExpectationsAnalysts currently expect Mylan to com...

  12. Teva Shares Higher After Copaxone Ruling

    Teva Pharmaceutical Industries Ltd. shares rose in premarket trading on Monday following a ruling by a federal judge regarding the company's patents on its flagship ...

  1. Actavis to Buy Warner Chilcott For $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  2. Novartis Considers Possible Bid for Actavis

    A heated takeover battle has erupted around generic-drug company Actavis Inc. (ACT) as industry players seek to shore themselves up amid increasing competition and f...

  3. Valeant to Launch Own Version of Generic Zovirax in Response to Mylan's

    Valeant Pharmaceuticals International Inc. (VRX, VRX.T) said it will launch a generic version of its Zovirax ointment Thursday after Mylan Inc. (MYL) received approv...

  4. Pfizer Gets Reissued Celebrex Patent, Extends Exclusivity

    Pfizer Inc. (PFE) could gain an additional 18 months of U.S. exclusivity--and monopoly sales--for its blockbuster painkiller Celebrex because the government effectiv...

  5. Pfizer Get Reissued Patent for Celebrex

    Pfizer Inc. (PFE) said the U.S. Patent & Trademark Office reissued a patent on the active ingredient in Celebrex, extending the painkiller's exclusivity to 2015 from...

  6. Market Wrap for Thursday, February 28: Stocks close Little Changed

    The stock market was little changed on Thursday as investors evaluated mixed economic reports.Jobless claims data and Chicago PMI was positive, but a second Q4 GDP e...

  7. Mylan 4th-Quarter Profit Up 25%, to Buy Agila Specialties for $1.6 Billion

    Mylan Inc.'s (MYL) fourth-quarter earnings rose 25% as the generics-drug maker reported revenue gains and unveiled plans to acquire Agila Specialties Private Ltd. fo...

‹ Prev123Next ›
Freebase CC-BY
Source: Mylan on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL